cephalosporin c has been researched along with cefiderocol in 217 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 38 (17.51) | 24.3611 |
| 2020's | 179 (82.49) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, A; Ito-Horiyama, T; Kohira, N; Nakamura, R; Rittenhouse, S; Sato, T; Tsuji, M; West, J; Yamano, Y | 1 |
| Ito, A; Matsumoto, S; Nakamura, R; Nishikawa, T; Sato, T; Tsuji, M; Yamano, Y; Yoshizawa, H | 1 |
| Arjona Ferreira, JC; Berg, JK; Echols, R; Galloway, C; Katsube, T; Krenz, HK | 1 |
| Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
| Fedler, KA; Flamm, RK; Huband, MD; Ito, A; Sader, HS; Tsuji, M | 1 |
| Echols, R; Hoover, J; Matsumoto, S; Nakamura, R; Rittenhouse, S; Singley, CM; Tsuji, M; Yamano, Y | 1 |
| Echols, R; Katsube, T; Kawaguchi, N; Wajima, T | 2 |
| Fukase, H; Katsube, T; Saisho, Y; Shimada, J; White, S | 1 |
| Choi, JJ; McCarthy, MW | 1 |
| Ghazi, IM; Monogue, ML; Nicolau, DP; Tsuji, M | 1 |
| Auguste, PS; Bumann, D; Köhler, T; Luscher, A; Mazza, L; Moynié, L; Naismith, JH; Pletzer, D | 1 |
| Hernandez-Illas, M; Katsube, T; Miyazaki, S; Narukawa, Y; Wajima, T | 1 |
| Aoki, T; Hasegawa, Y; Hisakawa, S; Kusano, H; Nakamura, R; Nishikawa, T; Nishitani, Y; Sano, M; Sato, J; Sato, T; Sugimoto, H; Tsuji, M; Yamano, Y; Yamawaki, K; Yokoo, K; Yoshizawa, H | 1 |
| Ishibashi, N; Ito, A; Ito-Horiyama, T; Nishikawa, T; Ota, M; Sato, T; Tsuji, M; Yamano, Y | 1 |
| Hsueh, PR; Hsueh, SC; Huang, YT; Lee, YJ; Liao, CH; Tsuji, M | 1 |
| Kieffer, N; Nordmann, P; Poirel, L | 1 |
| Ariyasu, M; Beale, R; Den Nagata, T; Edgeworth, JD; Jones, A; Jones, P; Livermore, DM; Merante, D; Patel, S; Roberts, P; Vithlani, S; Wyncoll, D; Young, C | 1 |
| Echols, R; Hackel, MA; Karlowsky, JA; Sahm, DF; Tsuji, M; Yamano, Y | 2 |
| Huttner, A | 2 |
| Ariyasu, M; Echols, R; Ferreira, JCA; Machida, M; Nagata, TD; Portsmouth, S; Tenke, P; van Veenhuyzen, D | 1 |
| Naber, KG; Wagenlehner, FME | 1 |
| Den Nagata, T; Echols, R; Portsmouth, S | 1 |
| Adam, HJ; Domalaon, R; Golden, AR; Idowu, T; Karlowsky, JA; Lagacé-Wiens, PRS; Lawrence, CK; Lynch Iii, JP; Noreddin, A; Schweizer, F; Walkty, AJ; Wiebe, K; Zelenitsky, S; Zhanel, GG; Zhanel, MA | 1 |
| Katsube, T; Miyazaki, S; Narukawa, Y; Shen, H; Tomek, C | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Hsueh, PR; Hsueh, SC; Jean, SS; Lee, WS | 1 |
| Furuie, H; Katsube, T; Saisho, Y; Shimada, J | 1 |
| Biamonte, E; Bruni, A; Garofalo, E; Liberto, MC; Lionello, R; Longhini, F; Marascio, N; Matera, G; Mazzitelli, M; Navalesi, P; Quirino, A; Scaglione, V; Serapide, F; Torti, C; Trecarichi, EM | 1 |
| Den Nagata, T; Katsube, T; Machida, M; Mason, JW; Migoya, E; Narukawa, Y; Sanabria, C; Stanworth, SH | 1 |
| Clancy, M; Stevens, RW | 1 |
| Echols, R; Katsube, T; Wajima, T | 1 |
| Page, MGP | 1 |
| Bonomo, RA | 1 |
| Sato, T; Yamawaki, K | 1 |
| Ariyasu, M; Echols, R; Nagata, TD | 1 |
| Yamano, Y | 1 |
| Alamarat, ZI; Arias, CA; Babic, J; Dinh, AQ; Gary, JL; Hanson, B; Miller, WR; Pérez, N; Tran, TT; Wanger, A; Wootton, SH | 1 |
| Shields, RK | 1 |
| Aitken, SL; Gerges, B; Prince, RA; Raad, I; Rolston, KVI; Shelburne, S | 1 |
| Aschenbrenner, DS | 1 |
| Adam, HJ; Baxter, M; Golden, AR; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 1 |
| Doi, Y; Iovleva, A; Kawai, A; Kline, EG; McElheny, CL; Shields, RK | 1 |
| Gallagher, JC | 1 |
| Conejo, MDC; Delgado-Valverde, M; Fernández-Cuenca, F; Pascual, Á; Serrano, L | 1 |
| McCarthy, MW | 1 |
| Doi, Y; Iovleva, A; Kawai, A; Kline, EG; McElheny, CL; Shields, RK; Sluis-Cremer, N | 1 |
| El-Lababidi, RM; Rizk, JG | 1 |
| Biswas, B; Bivens, BN; Brown, DE; Brownstein, MJ; Burch, AK; Daniels, R; Fackler, J; Gainey, AB; Horne, B; Malagon, F | 1 |
| Lee, YR; Yeo, S | 1 |
| Hackel, MA; Ishioka, Y; Kohira, N; Kuroiwa, M; Maki, H; Sahm, DF; Sato, T; Yamano, Y | 1 |
| Anacker, M; Castanheira, M; Johnson, JR; Johnston, BD; Porter, SB; Snippes Vagnone, P; Thuras, P; VonBank, B; Witwer, M | 1 |
| Patel, R; Simner, PJ | 1 |
| Albarri, O; AlMatar, M; Köksal, F; Makky, EA; Var, I | 1 |
| Blakely, KK; Stallworth, K; Weaver, K | 1 |
| Bergman, Y; Fissel, JA; Morris, CP; Simner, PJ; Tamma, PD; Tekle, T | 1 |
| Barnini, S; Casella, C; Falcone, M; Forfori, F; Guarracino, F; Leonildi, A; Malacarne, P; Menichetti, F; Nicastro, M; Tiseo, G; Vecchione, A | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| Heil, EL; Tamma, PD | 1 |
| Ariyasu, M; Bassetti, M; Doi, Y; Echols, R; Ferrer, R; Lodise, TP; Matsunaga, Y; Naas, T; Nagata, TD; Niki, Y; Paterson, DL; Portsmouth, S; Torre-Cisneros, J; Toyoizumi, K; Wunderink, RG | 1 |
| Ariyasu, M; Clevenbergh, P; Echols, R; Kaye, KS; Kollef, M; Matsunaga, Y; Menon, A; Nagata, TD; Pogue, JM; Shorr, AF; Timsit, JF; Wunderink, RG; Zeitlinger, M | 1 |
| Ceccarelli, G; De Angelis, M; Mastroianni, CM; Miele, MC; Oliva, A; Sacco, F; Venditti, M | 1 |
| Cherian, BP; Lampejo, T; Tan, MGM; Wareham, DW | 1 |
| Ibrahim, D; Jabbour, JF; Kanj, SS | 1 |
| Clevenbergh, P; Dernier, Y; Grande Perez, C; Huang, TD; Kamgang, P; Maillart, E; Miendje Deyi, VY | 1 |
| Felder-Scott, C; Greenberg, DE; Obuekwe, V; Pybus, CA | 1 |
| Abbaszadeh, F; Baradaran, B; Dehghani, L; Hasani, A; Rezaee, MA; Samadi Kafil, H; Vahhabi, A | 1 |
| Powers, JH | 1 |
| Bavaro, DF; Belati, A; Diella, L; Fico, C; Monno, L; Mosca, A; Romanelli, F; Ronga, L; Saracino, A; Stolfa, S | 1 |
| Alby, K; Alexander, J; Bartelt, LA; Brown, DE; Brownstein, MJ; Burch, AK; Carr, AL; Cheema, F; Daniels, R; Gainey, AB; Jones, MB; Lachiewicz, AM; Linder, KE; Longworth, S; Miller, MB; Shields, RK; Tompkins, KM; van Duin, D; Warner, NC | 1 |
| Farley, J; Goodwin, A; Higgins, K; Iarikov, D; Jang, SH; Nambiar, S; Naseer, S; Rubin, DB; Suvarna, K; Wei, X; Weinstein, EA | 1 |
| Al Obaidi, MM; Arias, CA; Dinh, AQ; Hanson, B; Khan, A; Lainhart, WD; Miller, WR; Streling, AP; Zangeneh, T | 1 |
| Kufel, WD; Mastro, KA; Parsels, KA; Steele, JM; Thomas, SJ | 1 |
| Chao, CM; Chen, CH; Hsueh, SC; Lai, CC; Wang, CY | 1 |
| André, C; Bennis, Y; Bodeau, S; Dupont, H; Kontar, L; Lemaire-Hurtel, AS; Mary, A; Mernissi, T; Zahr, N | 1 |
| Choby, JE; Jacob, JT; Ozturk, T; Satola, SW; Weiss, DS | 2 |
| Birgy, A; Bonacorsi, S; Choudhury, A; Cointe, A; Courroux, C; Hobson, CA; Jacquier, H; Magnan, M; Tenaillon, O | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Henriksen, AS; Longshaw, C; Stefani, S; Stracquadanio, S; Torti, E | 1 |
| Castagnola, E; Losurdo, G; Mariani, M; Medici, C; Mesini, A; Ugolotti, E | 1 |
| Heil, EL; McCreary, EK; Tamma, PD | 1 |
| Echols, R; Karas, A; Koren, A | 1 |
| Baquero-Artigao, F; Calvo, C; Del Rosal, T; Gerig, N; Gómez-Gil, MR; Grasa, CD; Moreno, F; Ochoa Fernández, B; San Román Pacheco, S | 1 |
| Pregnolato, M; Taccani, M; Terreni, M | 1 |
| Boutin, S; Fiedler, MO; Hackert, T; Heeg, K; Klein, S; Kocer, K; Mehrabi, A; Mieth, M; Nurjadi, D; Richter, D; Rupp, C; Störzinger, D; Tan, B; Weigand, MA; Zimmermann, S | 1 |
| Lee, YR | 1 |
| Clevenbergh, P; Maillart, E; Tulkens, PM | 1 |
| Abdul-Mutakabbir, JC; Castanheira, M; Kaye, KS; Kebriaei, R; Maassen, PT; Nguyen, L; Rybak, MJ; Stamper, KC | 1 |
| Adhikari, S; Cipko, K; Kizny Gordon, A; Konecny, P | 1 |
| Fratoni, AJ; Kuti, JL; Nicolau, DP | 1 |
| Abdelraouf, K; Gahara, Y; Gill, CM; Kuroiwa, M; Nakamura, R; Nicolau, DP; Oota, M; Takemura, M; Yamano, Y | 1 |
| Belcher, R; Zobell, JT | 1 |
| Bleibtreu, A; Funck-Brentano, C; Junot, H; Llopis, B; Luyt, CÉ; Noé, G; Paccoud, O; Robidou, P; Schlemmer, D; Tissot, N; Zahr, N | 1 |
| Nordmann, P; Poirel, L; Sadek, M | 1 |
| Cardenoso, L; Cercenado, E; Henriksen, AS; Longshaw, C; Pascual, A; Penin, R | 1 |
| Bain, M; Gant, V; Henriksen, AS; Hussain, A; Longshaw, C | 1 |
| Echols, R; Katsube, T; Matsunaga, Y; Menon, A; Nicolau, DP; Portsmouth, S; Rodvold, KA; Wajima, T; Wunderink, RG | 1 |
| Echols, RM; Nagata, T | 1 |
| Charmillon, A; D'Huart, E; Demoré, B; Loeuille, G; Vigneron, J | 1 |
| Bilal, M; Büsker, S; El Tabei, L; Fuhr, U; Krauss, C; Taubert, M | 1 |
| Chong, GL; Depypere, M; Desmet, S; Jacob, AS; Lagrou, K | 1 |
| Syed, YY | 1 |
| Alderete, JF; Cancio, LC; Carney, BW; Cindass, R; Markelz, AE; Rizzo, JA | 1 |
| Bianco, G; Boattini, M; Bondi, A; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
| Czech, M; Holubar, M; Ong'uti, S; Robilotti, E | 1 |
| Chandrasekaran, S; Contreras, D; Davar, K; Garner, OB; Price, TK; Simner, PJ; Ward, KW; Yang, S | 1 |
| Benvenuti, MR; Borghesi, L; Franzetti, M; Luzzaro, F; Mauri, C; Moioli, G; Montoli, M; Piconi, S; Viaggi, V | 1 |
| Hussar, DA | 1 |
| López-Medrano, F; Silva, JT | 1 |
| Adebayo, A; Ante, M; Beisken, S; Bergman, Y; Dzintars, K; Mostafa, HH; Simner, PJ; Tamma, PD; Tekle, T | 1 |
| Doi, Y; Fowler, EL; Iovleva, A; McElheny, CL; Shields, RK | 1 |
| Butler, D; Katsube, T; Tan, X; Wajima, T; Wenzler, E | 1 |
| Boutin, S; Chanthalangsy, Q; Heeg, K; Klein, S; Kocer, K; Nurjadi, D | 1 |
| Chakraborty, DS; Chatterjee, S; Choudhury, S; Lahiry, S | 1 |
| Chatfield, MD; Donaldson, A; Harris, PNA; Harris-Brown, T; Henderson, A; Lye, D; Paterson, DL; Wright, H | 1 |
| Caldwell, B; Hamprecht, A; Henriksen, AS; Longshaw, C; Thelen, P; Yamano, Y | 1 |
| Hsueh, PR; Ishibashi, N; Kuroiwa, M; Sheng, WH; Takemura, M; Yamano, Y | 1 |
| Arnouk, S; Lewis, TC | 1 |
| Echols, R; Matsunaga, Y; Menon, A; Portsmouth, S; Skaar, EP | 1 |
| Baylac, P; Bercot, B; Camelena, F; de Fontbrune, FS; Gras, J; Lafaurie, M; Molina, JM; Touratier, S; Valade, S; Villar-Fernandez, S; Xhaard, A | 1 |
| Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
| Byrne, D; Lai, L; Rose, L | 1 |
| Doi, Y; Echols, R; Matsunaga, Y; Nordmann, P; Shields, RK; Takemura, M; Yamano, Y | 1 |
| Kusaksizoglu, A; Nordmann, P; Poirel, L; Sadek, M | 1 |
| Gupta, A; Landman, D; Quale, J | 1 |
| Falcone, M; Tiseo, G | 2 |
| Baba, T; Echols, R; Paul, M; Portsmouth, S; Shields, RK; Timsit, JF; Yamano, Y | 1 |
| Bush, K; Carpenter, J; Chu, TY; Divoky, C; Lee-Hsiao, C; Neidig, N; Sultana, R; Threatt, H; Zhang, Q | 1 |
| Bennis, Y; Dubée, V; Jaubert, P; Luque-Paz, D; Mortaza, S; Wolff, M | 1 |
| Kahlmeter, G; Longshaw, C; Matuschek, E; Takemura, M; Yamano, Y | 1 |
| Barnini, S; Della Sala, L; Falcone, M; Farcomeni, A; Leonildi, A; Menichetti, F; Tiseo, G; Vecchione, A | 1 |
| Nordmann, P; Ortiz de la Rosa, JM; Poirel, L; Sadek, M | 1 |
| Kuai, J; Wang, H; Wang, X | 1 |
| Heil, EL; Hirsch, EB; Karaba, SM | 1 |
| Blandino-Ortiz, A; Montufar, J; Soriano, MC | 1 |
| Canton, R; Doi, Y; Simner, PJ | 1 |
| Bonnin, RA; Dortet, L; Emeraud, C; Jousset, AB; Naas, T | 1 |
| Badia, X; Calleja, MÁ | 1 |
| Danziger, LH; Drwiega, EN; Griffith, NC | 1 |
| Actis, LA; Bonomo, RA; Escalante, J; Georgeos, N; Mezcord, V; Nishimura, B; Pasteran, F; Pimentel, C; Ramirez, MS; Rodriguez, C; Sieira, R; Subils, T; Tolmasky, ME; Tuttobene, MR | 1 |
| Atkins, C; Babidhan, R; Covvey, JR; Gionfriddo, MR; Guarascio, AJ; Jozefczyk, NJ; Lewis, A; Montepara, CA; Nemecek, BD; Zimmerman, DE | 1 |
| Burd, EM; Davis, MH; Jacob, JT; Ozturk, T; Satola, SW; Steed, DB; Weiss, DS; Witt, LS | 1 |
| Adam, HJ; Baxter, MR; Bay, D; Karlowsky, JA; Lagacé-Wiens, PRS; Lynch, JP; Mulvey, MR; Schweizer, F; Walkty, AJ; Zhanel, GG | 1 |
| Amadesi, S; Ambretti, S; Gaibani, P; Lazzarotto, T | 1 |
| Fröhlich, C; Johnsen, PJ; Samuelsen, Ø; Sørum, V; Tokuriki, N | 1 |
| Huang, E; Jun, SR; Moon, SH; Udaondo, Z | 1 |
| Epling, BP; Powers, JH | 1 |
| Kusaksizoglu, A; Nordmann, P; Ortiz de la Rosa, JM; Poirel, L; Sadek, M; Sakaoglu, Z | 1 |
| Abouelhassan, Y; Bourdages, G; Gutierrez, RL; Kufel, WD; Nicolau, DP; Perwez, T; Steele, JM | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
| Brenner, T; Witzke, O | 1 |
| Jiang, Y; Lan, P; Lu, Y; Wu, X; Yu, Y; Zhou, J | 1 |
| Brazzi, L; Corcione, S; De Benedetto, I; De Rosa, FG; Lupia, T; Montrucchio, G; Pinna, SM; Vita, D | 1 |
| Karas, JA; Longshaw, CM; Santerre Henriksen, A; Slover, C; Yamano, Y | 1 |
| Dong, Y; Du, GF; Fan, X; Le, YJ; Yang, XY; Yin, A | 1 |
| Baba, T; Longshaw, C; Nguyen, S; Roger, E; Santerre Henriksen, A; Yamano, Y | 1 |
| Bivona, DA; Bonacci, PG; Bongiorno, D; Bonomo, C; Marino, A; Mirabile, A; Privitera, GF; Stefani, S; Stracquadanio, S | 1 |
| Burd, EM; Jacob, JT; Ozturk, T; Satola, SW; Weiss, DS; Witt, LS | 1 |
| Mensa, J; Soriano, A | 1 |
| Cantón, R; Castillo-Polo, JA; Gijón Cordero, D; Ruiz-Garbajosa, P | 1 |
| Azanza Perea, JR; Sádaba Díaz de Rada, B | 1 |
| Fariñas, MC | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Barberán, J; Mensa, J | 1 |
| Dela-Pena, J; Gavaghan, V; Miller, JL | 1 |
| Bouvier, M; Nordmann, P; Poirel, L; Sadek, M | 1 |
| Boutin, S; Heeg, K; Kocer, K; Nurjadi, D | 1 |
| Buonomo, AR; Catania, MR; Gentile, I; Grimaldi, F; Pane, F; Paolillo, R; Picardi, M; Pinchera, B; Zappulo, E | 1 |
| Bassetti, M; Castaldo, N; Giacobbe, DR; Grossi, PA; Peghin, M; Vena, A | 1 |
| Dessein, R; Gosset, P; Kipnis, E; Le Guern, R; Nordmann, P; Poirel, L; Sadek, M | 1 |
| Hua, X; Lei, T; Leptihn, S; Liu, H; Liu, X; Yang, Y; Yu, Y; Zhang, L | 1 |
| Boyer, P; Cristinar, M; Danion, F; Garijo, C; Hansmann, Y; Hoellinger, B; Jeannot, K; Lefebvre, N; Reisz, F; Ruch, Y; Schramm, F; Simand, C; Studer, A; Ursenbach, A | 1 |
| Campo, RD; Cantón, R; Castillo, MG; de Dios Caballero, J; Gomis-Font, MA; López-Causapé, C; Maruri-Aransolo, A; Mulet, X; Oliver, A; Penev, I | 1 |
| Bonomo, RA; Corso, A; Mezcord, V; Pasteran, F; Ramirez, MS; Tolmasky, ME; Wong, O | 1 |
| Alalwan, B; Alghoribi, MF; Aljohani, S; Alreheli, A; Alzayer, M; Bosaeed, M; Doumith, M | 1 |
| Cherian, BP; Kinzig, M; Sörgel, F; Stevenson, DR; Wareham, DW | 1 |
| Al-Marzooq, F; Collyns, T; Daoud, L; Ghazawi, A; Moubareck, CA | 1 |
| Biguenet, A; Bour, M; Devoos, L; Fournier, D; Jeannot, K; Plésiat, P; Rousselot, J | 1 |
| Andini, R; Durante-Mangoni, E; Karruli, A; Marrazzo, T; Massa, A; Ruocco, G; Zampino, R | 1 |
| Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L | 1 |
| Alvarado, K; Burnham, CD; Muenks, CE; Potter, RF; Wallace, MA; Yarbrough, ML | 1 |
| Laffont-Lozes, P; Larcher, R; Laureillard, D; Loubet, P; Naciri, T; Sotto, A | 1 |
| Stamm, P; Urmann, E; Wisskirchen, J | 1 |
| Mehringer, L; Seybold, U; Zoller, M | 1 |
| Domenech, J; Domenech, L; Ferrer, R; Gallart, E; García, S; Girón, P; Lamora, A; Nuvials, X; Palmada, C; Pau, A; Riera, J; Sánchez, A; Sosa, M; Torrella, P | 1 |
| Bleibtreu, A; Bonnin, RA; Dortet, L; Emeraud, C; Girlich, D; Jousset, AB; Naas, T; Poignon, C; Robert, J; Yilmaz, S | 1 |
| Danion, F; Hansmann, Y; Hoellinger, B; Ruch, Y; Schramm, F | 1 |
| Humphries, R; Lewis, JS; Mathers, AJ; Palavecino, EL; Satlin, MJ; Simner, PJ; Weinstein, MP | 1 |
| Boudour-Halil, D; Boutin, S; Chanthalangsy, Q; Heeg, K; Kocer, K; Nurjadi, D; Sähr, A | 1 |
| Carmona, P; Córdoba-Fernández, M; de la Fuente, C; Domínguez, A; García, L; Guzmán-Puche, J; López-Viñau, T; Machuca, I; Martínez-Martínez, L; Merino, N; Robles, JC; Rodríguez, M; Torre-Cisneros, J; Vaquero, JM | 1 |
| Huang, E; Moon, SH | 1 |
| Currie, BJ; Hagen, JP; Hall, CM; Keim, P; Mayo, M; Nottingham, R; Podin, Y; Sahl, JW; Schweizer, HP; Somprasong, N; Wagner, DM; Webb, JR | 1 |
| Dortet, L; Emeraud, C; Gonzalez, C | 1 |
| Alonso-Garcia, I; Alvarez-Fraga, L; Arca-Suárez, J; Beceiro, A; Bou, G; González-Bello, C; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Lence, E; Maceiras, R; Martinez-Guitian, M; Outeda, M; Peña-Escolano, A; Vázquez-Ucha, JC | 1 |
| Antonelli, A; Dortet, L; Frisch, S; Gatermann, S; Giani, T; Gonzalez, C; Hoenings, R; Naas, T; Niccolai, C; Pfennigwerth, N; Rossolini, GM | 1 |
| Cabot, G; Gomis-Font, MA; Oliver, A; Sastre-Femenia, MÀ; Taltavull, B | 1 |
| Dupont, H; Echols, R; Greenberg, DE; Kollef, M; Nicolau, DP; Viale, P; Yamano, Y | 1 |
| Casali, E; Medioli, F; Oliva, A; Pistolesi, V; Venditti, M; Viscido, A | 1 |
| Chang, Y; Hua, X; Huang, Z; Jiang, Y; Leptihn, S; Liu, X; Weng, S; Xu, Q; Yu, Y; Zhang, L; Zhang, W | 1 |
| Berry, AV; Conelius, A; Gluck, JA; Kuti, JL; Nicolau, DP | 1 |
| Hackel, MA; Sahm, DF; Takemura, M; Wise, MG; Yamano, Y | 1 |
| Akalin, H; Akova, M; Arabacı, Ç; Aslan, AT; Aydın, M; Azap, A; Azap, Ö; Bakır, VO; Balkan, İİ; Bauer, MJ; Can, F; Çınar, G; Demir, SK; Demirkaya, H; Doğan, Ö; Ergönül, Ö; Falconer, C; Forde, B; Gönen, M; Harris, PNA; Hazırolan, G; Isler, B; Kapmaz, M; Keske, Ş; Menekşe, Ş; Özer, B; Paterson, DL; Saltoğlu, N; Şimşek, F; Tigen, ET; Tülek, N; Vatansever, C; Yağcı, S | 1 |
| Bour, M; Da Silva, M; Jeannot, K; Landon, C; Plésiat, P; Vuillemin, X | 1 |
| Actis, LA; Bonomo, RA; Escalante, J; Mezcord, V; Nishimura, B; Pasteran, F; Ramirez, MS; Subils, T; Tolmasky, ME; Tuttobene, MR | 1 |
| Birer, A; Bonnin, RA; Bouabdallah, L; Dortet, L; Emeraud, C; Girlich, D; Glaser, P; Jousset, AB; Mariet, JF; Naas, T; Oueslati, S; Rosinski-Chupin, I | 1 |
| Ambretti, S; Gaibani, P; Lazzarotto, T; Viale, P | 1 |
| Costa, C; D'Avolio, A; Funiciello, E; Garazzino, S; Mignone, F; Mula, J; Pilloni, G; Ragazzi, P; Silvestro, E | 1 |
| Möhlmann, JE; Sikma, MA; Uijtendaal, EV; van Luin, M; Zahr, N | 1 |
| Bartolini, A; Bartoloni, A; Bernardo, M; Bianco, V; Botta, A; Faragona, A; Giacometti, A; Giani, T; Graziani, L; Lagi, F; Morroni, G; Parrella, R; Piccica, M; Rossolini, GM; Spinicci, M; Tavio, M | 1 |
| Al-Marzooq, F; Allam, M; Collyns, T; Daoud, L; Ghazawi, A; Saleem, A | 1 |
| Becker, K; Bohnert, JA; Bueter, A; Echelmeyer, T; Eger, E; Fickenscher, H; Guenther, S; Heiden, SE; Krumbholz, A; Maschkowitz, G; Nurjadi, D; Schaufler, K; Schwabe, M | 1 |
| Bouvier, M; Decousser, JW; Kerbol, A; Nordmann, P; Poirel, L; Raro, OHF | 1 |
| Al-Marzooq, F; Anes, F; Collyns, T; Daoud, L; Ghazawi, A | 1 |
40 review(s) available for cephalosporin c and cefiderocol
| Article | Year |
|---|---|
Cefiderocol: a novel siderophore cephalosporin.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Delivery Systems; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Siderophores | 2018 |
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Molecular Structure; Randomized Controlled Trials as Topic; Siderophores | 2019 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Kidney; Kidney Diseases; Kidney Function Tests | 2019 |
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Topics: Animals; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; History, 20th Century; Humans; Microbial Sensitivity Tests; Models, Molecular; Siderophores | 2019 |
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Resistance, Bacterial; Europe; Humans; United States; United States Food and Drug Administration | 2019 |
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans | 2019 |
Cefiderocol to treat complicated urinary tract infection.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; United States; Urinary Tract Infections | 2020 |
Cefiderocol: A Siderophore Cephalosporin.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Molecular Structure; Siderophores; Urinary Tract Infections | 2020 |
Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Siderophores; Urinary Tract Infections | 2020 |
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2020 |
An Overview of the Activities of Cefiderocol Against Sensitive and Multidrug- Resistant (MDR) Bacteria.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Microbial Sensitivity Tests; Molecular Structure | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Current choices of antibiotic treatment for Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; beta-Lactams; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Phage Therapy; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
A plethora of carbapenem resistance in
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteriophages; beta-Lactamases; beta-Lactams; Carbapenems; Cefiderocol; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Polymyxin B; Tetracyclines | 2021 |
Recurrent neurosurgical site infection by extensively drug-resistant
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Pharmaceutical Preparations; Pseudomonas aeruginosa | 2021 |
Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Cefiderocol; Cephalosporins; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
New Perspectives on Antimicrobial Agents: Cefiderocol.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines | 2021 |
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2021 |
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Double-Blind Method; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2021 |
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2022 |
Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2021 |
Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Adult; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Siderophores; Urinary Tract Infections | 2022 |
[Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
Topics: Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Microbial Sensitivity Tests; Siderophores | 2022 |
Cefiderocol.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans | 2022 |
Treatment of carbapenem-resistant
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System: the cefiderocol example.
Topics: Cefiderocol; Cephalosporins; Costs and Cost Analysis; Europe; Feasibility Studies; Technology Assessment, Biomedical | 2022 |
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Iron; Microbial Sensitivity Tests | 2022 |
Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review.
Topics: Animals; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Off-Label Use; Pseudomonas aeruginosa; Urinary Tract Infections | 2022 |
[Clinical experience using cefiderocol].
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Monobactams | 2023 |
Mechanism of action of cefiderocol.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cattle; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Iron; Quinolones; Serine; Tetracyclines | 2022 |
Antibacterial spectrum of cefiderocol.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catechols; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Iron; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Siderophores | 2022 |
Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.
Topics: Adult; Albumins; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood Proteins; Catechols; Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Humans; Iron; Meropenem | 2022 |
Clinical experience of cefiderocol.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pneumonia, Ventilator-Associated; Urinary Tract Infections | 2022 |
The role of cefiderocol in clinical practice.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Cefiderocol. Summary and conclusions.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2022 |
Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2022 |
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Prospective Studies; Randomized Controlled Trials as Topic | 2023 |
14 trial(s) available for cephalosporin c and cefiderocol
| Article | Year |
|---|---|
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Topics: Adult; Aged; Cefiderocol; Cephalosporins; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Renal Dialysis; Renal Insufficiency | 2017 |
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Weight; Case-Control Studies; Cefiderocol; Cephalosporins; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Models, Statistical; Pyelonephritis; Renal Insufficiency, Chronic; Severity of Illness Index; Siderophores; Urinary Tract Infections | 2018 |
Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Cefiderocol; Cephalosporins; Drug Administration Schedule; Drug Dosage Calculations; Female; Half-Life; Healthy Volunteers; Humans; Japan; Male; Middle Aged; Siderophores | 2018 |
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.
Topics: Adolescent; Adult; Biological Transport; Cefiderocol; Cephalosporins; Cross-Over Studies; Drug Interactions; Female; Furosemide; Humans; Male; Membrane Transport Proteins; Metformin; Middle Aged; Rosuvastatin Calcium; Siderophores; Young Adult | 2018 |
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Colony Count, Microbial; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Male; Middle Aged; Protease Inhibitors; Treatment Outcome; Urinary Tract Infections; Urine; Young Adult | 2018 |
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.
Topics: Adult; Cefiderocol; Cephalosporins; Drug Monitoring; Gram-Negative Bacteria; Healthy Volunteers; Humans; Lung; Male; Siderophores; Young Adult | 2019 |
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Healthy Volunteers; Heart; Heart Rate; Humans; Male; Moxifloxacin; Siderophores; Young Adult | 2019 |
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Sepsis; Urinary Tract Infections; Young Adult | 2021 |
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Healthcare-Associated Pneumonia; Humans; Male; Meropenem; Pneumonia, Bacterial | 2021 |
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; United States; United States Food and Drug Administration | 2021 |
Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomis
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Delivery of Health Care; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sepsis; Standard of Care | 2021 |
Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cross Infection; Double-Blind Method; Healthcare-Associated Pneumonia; Homeostasis; Humans; Iron | 2022 |
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Humans; Microbial Sensitivity Tests | 2022 |
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
163 other study(ies) available for cephalosporin c and cefiderocol
| Article | Year |
|---|---|
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Enterobacteriaceae; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Siderophores | 2016 |
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biological Transport; Carbon Radioisotopes; Cefiderocol; Ceftazidime; Cephalosporins; Fluoresceins; Fluorescent Dyes; Iron; Iron Chelating Agents; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Structure-Activity Relationship; Thiazoles | 2016 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Iron; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quality Control | 2017 |
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; Cefiderocol; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Klebsiella Infections; Klebsiella pneumoniae; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections | 2017 |
Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Azetidines; Cefepime; Cefiderocol; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Humans; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pyridones; Siderophores; Sulfonamides | 2018 |
TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Biological Transport; Carrier Proteins; Cefiderocol; Cell Membrane Permeability; Cephalosporins; Membrane Proteins; Monobactams; Pseudomonas aeruginosa; Siderophores; Thiazoles | 2018 |
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship | 2018 |
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2018 |
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Taiwan; Tazobactam | 2019 |
Stability of cefiderocol against clinically significant broad-spectrum oxacillinases.
Topics: Acinetobacter baumannii; Bacterial Proteins; beta-Lactamases; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests; Penicillin-Binding Proteins | 2018 |
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Aortic Valve; beta-Lactamases; Cefiderocol; Cephalosporins; Colistin; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Endocarditis, Bacterial; Female; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2019 |
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Topics: Acinetobacter; Anti-Bacterial Agents; Burkholderia cepacia; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; North America; Pseudomonas aeruginosa; Siderophores; Stenotrophomonas maltophilia | 2019 |
Cefiderocol in context.
Topics: Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Humans; Urinary Tract Infections | 2018 |
Cefiderocol for treatment of complicated urinary tract infections.
Topics: Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Humans; Urinary Tract Infections | 2019 |
Cefiderocol for treatment of complicated urinary tract infections.
Topics: Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Humans; Urinary Tract Infections | 2019 |
Cefiderocol for treatment of complicated urinary tract infections - Author's reply.
Topics: Cefiderocol; Cephalosporins; Cilastatin, Imipenem Drug Combination; Double-Blind Method; Humans; Urinary Tract Infections | 2019 |
Metabolism, Excretion, and Pharmacokinetics of [
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Area Under Curve; Cefiderocol; Cephalosporins; Feces; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Molecular Structure | 2019 |
Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
Topics: Cations, Divalent; Cefiderocol; Cephalosporins; Culture Media; Gram-Negative Bacteria; Iron; Microbial Sensitivity Tests; Reproducibility of Results; Siderophores | 2019 |
Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria.
Topics: Animals; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2019 |
Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Compassionate Use Trials; Critical Illness; Drug Resistance, Multiple, Bacterial; Humans; Influenza, Human; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pneumonia; Treatment Outcome | 2019 |
Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Humans; Intraabdominal Infections; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2019 |
The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics.
Topics: Bacterial Infections; beta-Lactams; Cefiderocol; Cephalosporins; Drug Design; Drug Development; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Iron; Models, Molecular; Siderophores | 2019 |
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Humans; Siderophores | 2019 |
Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefiderocol; Cephalosporins; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Nigeria; Osteomyelitis; Pseudomonas aeruginosa; Surgical Wound Infection | 2020 |
Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
Topics: Adolescent; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Osteomyelitis; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Siderophores | 2020 |
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Neoplasms; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2020 |
New Antibiotic for Complicated UTIs.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Administration Schedule; Drug Approval; Humans; Pyelonephritis; United States; United States Food and Drug Administration; Urinary Tract Infections | 2020 |
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Canada; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Siderophores; Stenotrophomonas maltophilia | 2020 |
Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacter cloacae; Humans; Microbial Sensitivity Tests | 2020 |
Bacteria Keep Reminding Us: There Are No Silver Bullets.
Topics: Azabicyclo Compounds; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacter cloacae; Humans; Silver | 2020 |
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Spain; Stenotrophomonas maltophilia | 2020 |
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacter cloacae; Microbial Sensitivity Tests | 2020 |
Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.
Topics: Achromobacter; Anti-Bacterial Agents; Bacteriophages; Boronic Acids; Cefiderocol; Cephalosporins; Child; Combined Modality Therapy; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem | 2020 |
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Siderophores | 2020 |
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Topics: Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Europe; Latin America; Microbial Sensitivity Tests; Phylogeny; Tetracyclines; United States | 2020 |
Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.
Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Urinary Tract Infections | 2020 |
Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2020 |
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Humans; Intensive Care Units; Microbial Sensitivity Tests; Prospective Studies | 2021 |
Cefiderocol: the Trojan horse has arrived but will Troy fall?
Topics: Bacteria; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria | 2021 |
Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Humans | 2020 |
Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection.
Topics: Bacterial Proteins; beta-Lactamases; Cefiderocol; Cephalosporins; Klebsiella pneumoniae | 2020 |
Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance.
Topics: Abscess; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Cefiderocol; Cephalosporins; Compassionate Use Trials; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Male; Middle Aged; Pancreatitis; Pseudomonas aeruginosa; Staphylococcus aureus; Treatment Outcome | 2021 |
Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.
Topics: Anti-Bacterial Agents; Biofilms; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
Topics: Anti-Bacterial Agents; Bacteremia; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pneumonia; Sepsis; Siderophores; Urinary Tract Infections | 2021 |
Scientific Evidence, Regulatory Decision Making, and Incentives for Therapeutics in Infectious Diseases: The Example of Cefiderocol.
Topics: Cefiderocol; Cephalosporins; Communicable Diseases; Decision Making; Humans; Microbial Sensitivity Tests; Motivation; United States; United States Food and Drug Administration | 2021 |
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
Topics: Achromobacter denitrificans; Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans | 2021 |
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Siderophores | 2021 |
An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Chromatography, High Pressure Liquid; Critical Illness; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2021 |
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
Topics: Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans | 2021 |
Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2021 |
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
Topics: Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Europe; Italy; Pseudomonas aeruginosa | 2021 |
Colonization by Escherichia coli strains with increased minimal inhibitory concentration for cefiderocol: When resistance anticipates drug use.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Pharmaceutical Preparations | 2021 |
Comment on 'Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety'.
Topics: Cefiderocol; Cephalosporins; Humans; Siderophores; Urinary Tract Infections | 2021 |
Compassionate use of cefiderocol for VIM metallo-β-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma.
Topics: beta-Lactamases; Burkitt Lymphoma; Cefiderocol; Cephalosporins; Child, Preschool; Compassionate Use Trials; Humans; Pseudomonas Infections | 2021 |
Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Enterobacter cloacae; Humans; Microbial Sensitivity Tests; Mutation; Siderophores | 2022 |
Response to "Comment on: Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety".
Topics: Cefiderocol; Cephalosporins; Humans; Siderophores; Urinary Tract Infections | 2021 |
Reply to: 'Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomised controlled trials'.
Topics: Bacterial Infections; Cefiderocol; Cephalosporins; Humans; Treatment Outcome | 2021 |
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests | 2021 |
Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Nephritis, Interstitial; Pharmaceutical Preparations; Pseudomonas aeruginosa | 2021 |
Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Coinfection; Continuous Renal Replacement Therapy; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Stenotrophomonas maltophilia | 2021 |
Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models.
Topics: Animals; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Mice; Microbial Sensitivity Tests; Stenotrophomonas maltophilia | 2021 |
Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol.
Topics: Anti-Bacterial Agents; Boronic Acids; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem | 2021 |
Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.
Topics: Cefiderocol; Cephalosporins; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Isotopes; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests | 2021 |
In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Spain | 2021 |
In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2021 |
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Pneumonia; Respiration, Artificial | 2021 |
US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication.
Topics: Cefiderocol; Cephalosporins; Humans; Urinary Tract Infections | 2021 |
Physicochemical stability of cefiderocol, a novel siderophore cephalosporin, in syringes at 62.5 mg/mL for continuous administration in intensive care units.
Topics: Cefiderocol; Cephalosporins; Intensive Care Units; Monobactams; Polypropylenes; Siderophores; Syringes | 2023 |
No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests | 2021 |
Carbapenem-Resistant Enterobacterales Infection After Massive Blast Injury: Use of Cefiderocol Based Combination Therapy.
Topics: Anti-Bacterial Agents; Blast Injuries; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Humans; Male; Microbial Sensitivity Tests | 2021 |
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Escherichia coli; Genomics; Humans; Microbial Sensitivity Tests | 2022 |
Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report.
Topics: Cefiderocol; Cephalosporins; COVID-19; Empyema, Pleural; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
New Drugs 2021, Part 2.
Topics: Adenosine Monophosphate; Alanine; Amisulpride; Carbamates; Cefiderocol; Cephalosporins; Chlorophenols; COVID-19 Drug Treatment; Drug Approval; Drug Combinations; Fumarates; Humans; Indans; Organophosphates; Oxadiazoles; Piperazines; Spiro Compounds; Tetrazoles; Thiophenes; Tromethamine; United States; United States Food and Drug Administration | 2021 |
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; DNA Copy Number Variations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Plasmids; RNA, Messenger | 2022 |
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Cation Transport Proteins; Cefiderocol; Cephalosporins; Codon, Nonsense; Drug Resistance, Multiple, Bacterial; Frameshift Mutation; High-Throughput Nucleotide Sequencing; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Siderophores | 2021 |
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Bayes Theorem; Cefiderocol; Cephalosporins; Clinical Trials, Phase III as Topic; Continuous Renal Replacement Therapy; Critical Illness; Humans; Microbial Sensitivity Tests; Renal Replacement Therapy | 2022 |
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Microbial Sensitivity Tests | 2022 |
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Tazobactam | 2022 |
Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Iron; Multilocus Sequence Typing; Siderophores; Taiwan | 2022 |
Dark Red Urine in a Patient on Cefiderocol and Ferric Gluconate.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Ferric Compounds; Humans; Kidney Diseases; Microbial Sensitivity Tests | 2022 |
Successful cefiderocol therapy of severe infections due to difficult-to-treat Pseudomonas aeruginosa in two allogeneic hematopoietic stem cell transplantation recipients.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hematopoietic Stem Cell Transplantation; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: A case report.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis | 2022 |
Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Cefiderocol for the Treatment of Metallo-β-Lactamases Producing Gram-Negative Bacilli: Lights and Shadows From the Literature.
Topics: beta-Lactamases; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans | 2022 |
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cerebral Ventriculitis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Escherichia coli; Gram-Negative Bacteria; Iron; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Reproducibility of Results | 2022 |
Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Colistin; Humans; Pneumonia, Ventilator-Associated; Retrospective Studies; Sepsis | 2022 |
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Escherichia coli Infections; Humans; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
In a Pinch: Cefiderocol for CRAB Infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Retrospective Studies | 2022 |
Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Reproducibility of Results | 2022 |
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
Topics: Cefiderocol; Cephalosporins; Clinical Trials as Topic; Humans | 2021 |
Acinetobacter baumannii response to cefiderocol challenge in human urine.
Topics: Acinetobacter baumannii; Albumins; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Humans; Iron; Microbial Sensitivity Tests; Siderophores | 2022 |
Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
Evolution of β-lactamase-mediated cefiderocol resistance.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Microbial Sensitivity Tests | 2022 |
Cefiderocol heteroresistance in Klebsiella pneumoniae is linked to mutations in the siderophore receptor cirA and β-lactamase activities.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Mutation; Siderophores | 2022 |
Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2022 |
NDM-35-Producing ST167
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests | 2022 |
Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".
Topics: Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests | 2022 |
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Female; Gentamicins; Humans; Meningitis; Microbial Sensitivity Tests; Middle Aged | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Iron; Klebsiella pneumoniae; Microbial Sensitivity Tests; Siderophores | 2022 |
Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
Topics: Adolescent; Aged; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Middle Aged; Retrospective Studies | 2022 |
Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Proteomic Investigation of the Antibacterial Mechanism of Cefiderocol against Escherichia coli.
Topics: Acetylcysteine; Anti-Bacterial Agents; Antioxidants; Ascorbic Acid; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Deferoxamine; Escherichia coli; Flavin-Adenine Dinucleotide; Hydrogen Peroxide; Iron; NAD; NADP; Proteomics; Quinones; Reactive Oxygen Species; Siderophores; Sulfur | 2022 |
Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests | 2022 |
Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Penicillin-Binding Proteins | 2022 |
'Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance'-authors' response.
Topics: Bacteremia; Cefiderocol; Cephalosporins; Humans; Klebsiella Infections; Klebsiella pneumoniae | 2022 |
Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Retrospective Studies; Salvage Therapy | 2023 |
Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
The acquisition of transferable extrachromosomal fec operon is associated with a cefiderocol MIC increase in Enterobacterales.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Operon; Receptors, Cell Surface; RNA, Messenger | 2022 |
Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Pneumonia; Stenotrophomonas maltophilia | 2022 |
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Microbial Sensitivity Tests | 2022 |
Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2023 |
Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Genomics; Humans; Iron; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests | 2023 |
In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Gram-Negative Bacteria; Klebsiella pneumoniae; Pseudomonas aeruginosa; Saudi Arabia | 2023 |
Intravenous cefiderocol for neurosurgical meningitis from an extensively drug-resistant New-Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa strain.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Pseudomonas aeruginosa | 2023 |
Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Iron; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Siderophores | 2022 |
Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol.
Topics: Agar; Anti-Bacterial Agents; Cefiderocol; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
Topics: Aged; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Retrospective Studies; Treatment Outcome | 2023 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller-Hinton Agar.
Topics: Agar; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; United States | 2023 |
Re: 'Real world clinical outcome of cefiderocol for treatment of multidrug-resistant nonfermenting gram-negative bacilli infections' by Hoellinger et al.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2023 |
[Cefiderocol in AML patient with neutropenic infection due to 4MRGN Klebsiella pneumoniae (VIM-1)].
Topics: Aged; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Communicable Diseases; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Neoplasm Recurrence, Local; Neutropenia | 2023 |
[What is new … cefiderocol].
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins | 2023 |
Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Extracorporeal Membrane Oxygenation; Humans; Monobactams | 2023 |
Rapid selection of a cefiderocol-resistant Escherichia coli producing NDM-5 associated with a single amino acid substitution in the CirA siderophore receptor.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Microbial Sensitivity Tests; Siderophores | 2023 |
Re: real world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting gram-negative bacilli infections: author's response.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2023 |
Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests | 2023 |
Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Enterobacteriaceae Infections; Escherichia coli; Genomics; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Phenotype; Siderophores | 2023 |
Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies; Salvage Therapy | 2023 |
Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Escherichia coli; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins | 2023 |
Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei.
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Microbial Sensitivity Tests | 2023 |
Comparison of ComASP® and UMIC® methods with the reference method for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests | 2023 |
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Enterobacter cloacae; Microbial Sensitivity Tests; Siderophores | 2023 |
Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans; Iron; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
First case of persistent Stenotrophomonas maltophilia bacteraemia due to septic thrombosis successfully treated with a cefiderocol-containing regimen.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Stenotrophomonas maltophilia | 2023 |
Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence in
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Membrane Transport Proteins; Mutation; Virulence | 2023 |
Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Critical Illness; Extracorporeal Membrane Oxygenation; Humans | 2023 |
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefiderocol; Cephalosporins; Europe; Gram-Negative Bacteria; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Higher rates of cefiderocol resistance among NDM producing
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Humans; Klebsiella; Microbial Sensitivity Tests | 2023 |
Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Human serum albumin-induced modification of Ton-B-dependent receptor expression in cefiderocol-exposed carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests | 2023 |
Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France.
Topics: Cefiderocol; Cephalosporins; Escherichia coli; Europe; France; Gammaproteobacteria | 2023 |
In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Cephalosporins; Drug Combinations; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests | 2023 |
Plasmatic and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa meningoencephalitis.
Topics: Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |
Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Female; Humans | 2023 |
Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.
Topics: Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Retrospective Studies | 2023 |
Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genomics; Humans; Klebsiella pneumoniae; Sepsis; Siderophores | 2023 |
Convergent
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Disease Outbreaks; Klebsiella pneumoniae; Multilocus Sequence Typing | 2023 |
Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2023 |
High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefiderocol; Cephalosporins; Hospitals; Humans; Inpatients; Iron; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Siderophores; United Arab Emirates | 2023 |